Juno Therapeutics, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Juno Therapeutics, Inc. (JUNO) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of Juno Therapeutics, Inc. (NASDAQGS: JUNO) breached their fiduciary duty to shareholders by engaging in self-dealing and issuing materially false and misleading statements regarding the side effects of its lead product candidate, JCAR015.

Investors Survive Defendants’ Motion to Dismiss in Securities Class Action

Juno is currently the subject of a federal securities class action alleging that between June 4, 2016 and November 22, 2016, Juno officials understated the risks associated with JCAR015. In July 2016, in addition to finally disclosing several patient deaths associated with the drug, Juno revealed that the FDA issued a clinical hold. On June 14, 2017, U.S. District Judge Ricardo Martinez issued an order in the securities class action denying defendants’ motion to dismiss.

Juno Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003 or you can complete the form below and we will contact you directly.

 

Shareholder Information

Items marked with an asterisk (*) are required information.

First Name * Last Name *
Phone *
E-mail * Confirm: E-mail *
Number of Shares Owned:
Comments:

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

* I have read the disclaimer information
+=

    Send This Post